March 27, 2023
To whom it may concern
Company: Teijin Limited
Representative: Akimoto Uchikawa, President and CEO Stock code: 3401 (Prime Market, Tokyo Stock Exchange)
Contact: Tomoya Yoshitomi, General Manager,
Investor and Public Relations Department
TEL: +81-3-3506-4395
Notice Regarding Dividends Received from Consolidated Subsidiaries
Teijin Limited (hereinafter, the "Company") today received dividends from two consolidated subsidiaries of the Company. As a result, there will be an impact on the Company's non-consolidated financial results, as announced below.
1. Outline
(1) Date of receipt of dividends: March 27, 2023
(2) Amount of dividends:
Company Name | Amount of Dividends |
TEIJIN PHARMA LIMITED | ¥24,000 million |
TEIJIN FRONTIER CO., LTD. | ¥4,500 million |
2. Impact on Financial Results
As a result of the receipt of these dividends, the Company will record the dividends income of ¥28,500 million as non-operating income in its non-consolidated financial results for FY2022, the fiscal year ending March 31, 2023.
There will be no impact on the consolidated financial results for FY2022, as these dividends are from consolidated subsidiaries.
- End -
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Teijin Limited published this content on 27 March 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 March 2023 08:37:09 UTC.